MetaGen-ImmunoVest 3rd GO Vest™

NK Cell Rescue

Designed to rescue the patient’s native natural killer cell (NK cell) population

Long-lasting

24/7 serial cancer cell killer, without the need to transplant NK cells in patients or be co-administered with therapeutic agents

Self-sustaining

Unique ability to be self-sustaining, self-activating, target-directed NK cell therapeutic agent

Cost-effective

Significantly less expensive than other cancer treatments, opening the door to an off-the-shelf therapeutic for patients

3rd GO Vest™ Design

2 Single Chain Variable Fragments (ScFv) Crosslinked with Human IL-15

  • 1st ScFv recognizes the anti-CD16 marker on NK cells
  • Human IL-15 crosslinking with both ScFv, provides a self-sustaining signal that activates NK cells and enhances their ability to kill tumor cells
  • 2nd ScFv recognizes a marker expressed on the tumor cell

3rd GO Vest™ Mechanism of Action

Simultaneously reacts with natural killer cells and cancer cells to selectively facilitate the killing of cancer cells by NK cells

Limited Adverse Cytokine Release

Due to selective sequestering IL-15 directly to the immune synapse at the site of the cancer instead of being delivered throughout the entire body via intravenous systemic delivery leading to adverse cytokine storm release syndrome.

3 Aspects of Humoral Antibody Response

  • Ability to mediate antibody dependent cellular cytotoxicity (ADCC) through CD16
  • Ability to mediate in vivo expansion of the immune **population to recruit more NK cells to generate an anti-cancer response (IL-15 linker)
  • Recognition of cancer cell’s target tumor antigen